1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

1. A compound of formula I:

in which:

m is selected from 0, 1 and 2;

p is 1;

Y 1 is selected from CH and N;

Y 2 is selected from CR 6 and N;

Y 3 is CR 7 R 8 ;

R 1 is selected from C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S;

wherein said aryl or heteroaryl of R 1 is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, C 1-4 alkoxy, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 and —NHC(O)R 10 ;

R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

R 3a and R 3b are independently selected from hydrogen, halo, carbonyl, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

R 4a and R 4b are independently selected from hydrogen, halo, carbonyl, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

R 5a and R 5b are independently selected from hydrogen, carbonyl, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

wherein any two groups selected from R 2a , R 3a , R 4a and R 7 can form a 5 to 6 member unsaturated, partially unsaturated ring or saturated ring optionally containing a ring nitrogen;

R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino-carbonyl, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, —S(O) 1-2 R 6a , —C(S)R 6a , —C(O)NR 6a R 6b , —C(NH)NR 6a R 6b and —NR 6a C(O)R 6b ; wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;

R 7 is selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, C 6-10 aryl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S;

or R 7 and R 4a together with the carbon atoms to which they are both attached can form a pyrrolidinyl or cyclopropyl group optionally substituted with amino;

R 8 is selected from amino, amino-methyl and methyl-amino;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of Formula Ia:

in which:

m is selected from 0 and 1;

n is selected from 1, 2, 3, 4 and 5;

Y 1 is selected from CH and N;

Y 2 is selected from CR 6 and N;

R 4a is selected from hydrogen, methyl and hydroxy;

R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino-carbonyl, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, —S(O) 1-2 R 6a , —C(S)R 6a , —C(O)NR 6a R 6b , —C(NH)NR 6a R 6b and NR 6a C(O)R 6b ; wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;

R 7 is selected from hydrogen, methyl, phenyl, pyrazinyl and pyridinyl;

or R 7 and R 4a together with the carbon atoms to which they are both attached can form a cyclopropyl group substituted with amino;

R 8 is selected from amino and methyl-amino;

R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 and —NHC(O)R 10 ;

R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , or the pharmaceutically acceptable salt thereof, selected from:

4. The compound of claim 1 of formula Ib:

in which:

Y 1 is selected from CH and N;

Y 2 is selected from CR 6 and N;

R 1 is selected from thiophen-2-yl and 1H-indol-7-yl; wherein said thiophen-2-yl can be substituted with a group selected from methyl and chloro;

R 6 is selected from hydrogen, halo and methyl;

R 8 is selected from amino and methyl-amino;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , or the pharmaceutically acceptable salt thereof, selected from:

6. A compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1 , or the pharmaceutically acceptable salt thereof, selected from:

8. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

9. A method of treatment comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a person in need of such treatment in an effective amount for the therapeutic treatment of a disease or disorder which is mediated by the activity of SHP2.

10. The method of claim 9 , wherein the disease or disorder mediated by the activity of SHP2 is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.